Little is known on the thresholds of cardiovascular risk and degree of benefit at which subjects would be willing to take regular, lifelong antihypertensive treatment. We asked doctors, the general public and hypertensives to imagine that they were hypertensive and to consider the level of cardiovascular risk at which they would take an antihypertensive to reduce their risk. Acceptance of antihypertensive treatment was similarly distributed amongst doctors and the general public, but patients known to have hypertension generally accepted treatment at lower levels of risk. Guidelines on hypertension suggest targets for blood pressure control and encourage the use of antihypertensive drugs, if these are required, to reach target values. [1] [2] [3] [4] However, there has been very little work on the extent of benefit from antihypertensives that individuals would consider acceptable before opting to take regular treatment. There is some evidence that when fully informed of the likely benefit of treatment, many patients may be unwilling to accept cholesterol-lowering treatment. 5 To make a fully informed decision on whether or not to take regular, lifelong antihypertensive drugs, an individual patient needs to know the likely benefits and possible adverse effects of treatment. Where possible, the potential benefits of treatment should be communicated in terms of absolute, rather than relative, reduction in cardiovascular risk. 6 The aim of this study was to investigate the thresholds of cardiovascular risk and absolute benefit of treatment at which doctors (without known hypertension), the general public (without known hypertension) and hypertensive patients (from primary and secondary care hypertension clinics), all without a history of a cardiovascular event, would take lifelong antihypertensive drug therapy.
Subjects underwent a brief structured interview. They were asked to consider that they had hypertension for which they were being offered a tablet to take once daily for life. They were told that the chance of side effects was 10-20% 7 (details only being revealed if the subject asked), that they would have to see a doctor or nurse 6-monthly and that they may need occasional blood tests. They were also told to assume that their hypertension had persisted despite lifestyle changes. Using specially designed Risk Demonstrator Cards, subjects were presented with 10 scenarios, each depicting different levels of baseline cardiovascular risk from 3 to 100%, and the anticipated effect of treatment. For all scenarios, the relative risk reduction of treatment was 30% over 10 years, if anything probably a slight overestimate of the benefit over this time frame. 8 The effect of treatment was presented as the absolute benefit when given to 100 people for 10 years. 6 Both in graphic and written forms, subjects were informed of the number of people in whom a heart attack or stroke would be prevented, the number who would not benefit either because they would not have an event anyway or because they would have an event despite treatment, and the number needed to treat to prevent one event. Subjects were asked to state at which scenario they would take treatment. The written instructions and the scenarios are available online.
One hundred and fifty subjects in each of the three groups completed the questionnaire. Of the doctors, 28 (19%) were general practitioners and 122 (81%) were hospital doctors (81 (66%) in training grades, 41 (34%) consultants). Seventy-seven per cent of doctors would accept treatment at a 10-year cardiovascular risk of 20% or lower (the threshold at which the British Hypertension Society recommend treatment). 4 A similar proportion of the general public, 71%, would also accept treatment at this level of risk (95% confidence interval (CI) of the difference between doctors and the general public À3 to 16%, P ¼ 0.19). In contrast, a higher proportion of hypertensive patients, 91%, would accept treatment at a 10-year risk of 20% or lower (95% CI of the difference between doctors and patients À22 and À6%, P ¼ 0.001, and between the general public and patients À29 and À12%, Po0.0001). The data are shown in the Figure 1 .
The distributions of responses from the doctors and general public were similar despite differences in knowledge, understanding and experience of both hypertension and its consequences and of antihypertensive drugs. This is perhaps reassuring, because doctors are in a position to influence patients' decisions on accepting treatment and their own concept of what constitutes 'worthwhile' risk reduction has the potential to affect how strongly they recommend or do not recommend treatment. However, even though overall the responses were similar, there is clearly still scope for significant mismatch between individual doctor and individual patient, and doctors should keep in mind that their view on whether a patient should take regular treatment may be significantly at odds with the patient's view.
The appreciable variation in the threshold of cardiovascular risk at which subjects, particularly doctors and the general public, would accept antihypertensive treatment, underscores the importance of fully and honestly informing patients of the likely benefits, as well as risks, of drug therapy. For example, current British Hypertension Society guidelines recommend treatment of grade 1 hypertension if the overall 10-year cardiovascular disease risk is X20%. 4 Although a majority of subjects in each of the three groups would be concordant with a treatment decision if it had been informed by these guidelines, significant numbers (23% of doctors, 29% of the general public and 6% of hypertensives) would only accept treatment at higher levels of risk (30% or greater).
A remarkable finding was the proportion of all groups that would apparently accept treatment at lower levels of cardiovascular risk and absolute benefit in spite of a thorough visual and mathematical illustration of the outcome. A majority of subjects would take treatment at a 10-year risk of 10% or lower (56% of doctors, 51% of the general public and 86% of hypertensives) and many would take treatment at 3% risk (22, 29 and 55%, respectively). Particularly, striking is the apparent impact of being labelled as hypertensive and coming under regular medical review on the perceived acceptability of chronic therapy. Although most of the hypertensives were taking regular antihypertensive therapy, this finding illustrates the potential for the medical process itself to boost its own perceived utility and, in particular, the powerful influence on patients of their doctor's recommendation.
We acknowledge a number of study limitations. Subjects were presented with a hypothetical scenario and thresholds for accepting treatment might be modified by the reality of being diagnosed with hypertension. The thresholds might also be modified by knowledge that two or more drugs are often needed to control hypertension. The Framingham risk equation calculates cardiovascular risk over 10 years, whereas clinical trials of antihypertensive therapy typically have follow-up periods of around 5 or 6 years. We have assumed that the relative benefits of treatment on cardiovascular events are the same at 10 years as has been shown in the trials.
The manner in which risk and risk modification were presented in this study appeared to facilitate good understanding of the risks and benefits of treatment among the participants and could form the basis of clinical tools for risk communication in clinical practice. For example, patientspecific information could easily be obtained if the Figure 1 Frequency distributions for the thresholds of 10-year cardiovascular risk at which doctors, the general public and hypertensives would be willing to take lifelong antihypertensive drug treatment. Cumulative percentages are shown below the bars. Two doctors and two hypertensives would not take the treatment at any level of risk.
What is known about this topic K There is some evidence that, when fully informed of the likely benefit of treatment, many patients may be unwilling to take drugs to prevent cardiovascular disease.
What this study adds K The thresholds of risk and absolute benefit at which doctors and the general public would accept antihypertensive drug treatment are similar. K Hypertensives already taking treatment would accept drug therapy at much lower levels of risk and absolute benefit. methodology was computerized. A similar approach could also be used in further research on attitudes to drug treatment, for example, in newly diagnosed hypertensives.
